These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 12880500)

  • 21. Continued cognitive-behavior therapy versus sertraline for children and adolescents with obsessive-compulsive disorder that were non-responders to cognitive-behavior therapy: a randomized controlled trial.
    Skarphedinsson G; Weidle B; Thomsen PH; Dahl K; Torp NC; Nissen JB; Melin KH; Hybel K; Valderhaug R; Wentzel-Larsen T; Compton SN; Ivarsson T
    Eur Child Adolesc Psychiatry; 2015 May; 24(5):591-602. PubMed ID: 25239489
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of comorbidity on treatment response to paroxetine in pediatric obsessive-compulsive disorder: is the use of exclusion criteria empirically supported in randomized clinical trials?
    Geller DA; Biederman J; Stewart SE; Mullin B; Farrell C; Wagner KD; Emslie G; Carpenter D
    J Child Adolesc Psychopharmacol; 2003; 13 Suppl 1():S19-29. PubMed ID: 12880497
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of selective serotonin reuptake inhibitors on thought-action fusion, metacognitions, and thought suppression in obsessive-compulsive disorder.
    Besiroglu L; Çetinkaya N; Selvi Y; Atli A
    Compr Psychiatry; 2011; 52(5):556-61. PubMed ID: 21109243
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Placebo-controlled, multicenter study of sertraline treatment for obsessive-compulsive disorder.
    Kronig MH; Apter J; Asnis G; Bystritsky A; Curtis G; Ferguson J; Landbloom R; Munjack D; Riesenberg R; Robinson D; Roy-Byrne P; Phillips K; Du Pont IJ
    J Clin Psychopharmacol; 1999 Apr; 19(2):172-6. PubMed ID: 10211919
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Drug concentration monitoring with tolerability and efficacy assessments during open-label, long-term sertraline treatment of children and adolescents.
    Alderman J; Wolkow R; Fogel IM
    J Child Adolesc Psychopharmacol; 2006; 16(1-2):117-29. PubMed ID: 16553533
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Double-blind study of dextroamphetamine versus caffeine augmentation for treatment-resistant obsessive-compulsive disorder.
    Koran LM; Aboujaoude E; Gamel NN
    J Clin Psychiatry; 2009 Nov; 70(11):1530-5. PubMed ID: 19573497
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Agomelatine augmentation of sertraline in the treatment of moderate to severe obsessive-compulsive disorder: a randomized double-blinded placebo-controlled clinical trial.
    Shokrani M; Askari S; Eissazade N; Shariat SV; Shariati B; Yarahmadi M; Shalbafan M
    BMC Psychiatry; 2023 Sep; 23(1):686. PubMed ID: 37735631
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Multicenter double-blind comparison of sertraline and desipramine for concurrent obsessive-compulsive and major depressive disorders.
    Hoehn-Saric R; Ninan P; Black DW; Stahl S; Greist JH; Lydiard B; McElroy S; Zajecka J; Chapman D; Clary C; Harrison W
    Arch Gen Psychiatry; 2000 Jan; 57(1):76-82. PubMed ID: 10632236
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Personality traits as predictors for treatment response to sertraline among unmedicated obsessive-compulsive Disorder: A 12-weeks retrospective longitudinal study.
    Zhang J; Zhong H; Zhang Y; Yin J; Song X; Ye K; Song Z; Lai S; Zhong S; Wang Z; Jia Y
    J Psychiatr Res; 2024 Feb; 170():245-252. PubMed ID: 38171218
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder using adjunctive olanzapine: a placebo-controlled trial.
    Bystritsky A; Ackerman DL; Rosen RM; Vapnik T; Gorbis E; Maidment KM; Saxena S
    J Clin Psychiatry; 2004 Apr; 65(4):565-8. PubMed ID: 15119922
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment Gains Are Sustainable in Pediatric Obsessive-Compulsive Disorder: Three-Year Follow-Up From the NordLOTS.
    Melin K; Skarphedinsson G; Thomsen PH; Weidle B; Torp NC; Valderhaug R; Højgaard DRMA; Hybel KA; Nissen JB; Jensen S; Dahl K; Skärsäter I; Haugland BS; Ivarsson T
    J Am Acad Child Adolesc Psychiatry; 2020 Feb; 59(2):244-253. PubMed ID: 30768383
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Treatment of comorbid obsessive-compulsive and depressive disorders in children age].
    Goriunov AV; Lobacheva MV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2012; 112(11 Pt 2):48-52. PubMed ID: 23257756
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A 1 year double-blind placebo-controlled fixed dose study of sertraline in the treatment of obsessive-compulsive disorder.
    Greist JH; Jefferson JW; Kobak KA; Chouinard G; DuBoff E; Halaris A; Kim SW; Koran L; Liebowtiz MR; Lydiard B
    Int Clin Psychopharmacol; 1995 Jun; 10(2):57-65. PubMed ID: 7673657
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Use of factor-analyzed symptom dimensions to predict outcome with serotonin reuptake inhibitors and placebo in the treatment of obsessive-compulsive disorder.
    Mataix-Cols D; Rauch SL; Manzo PA; Jenike MA; Baer L
    Am J Psychiatry; 1999 Sep; 156(9):1409-16. PubMed ID: 10484953
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Quetiapine addition to serotonin reuptake inhibitors in patients with severe obsessive-compulsive disorder: a double-blind, randomized, placebo-controlled study.
    Kordon A; Wahl K; Koch N; Zurowski B; Anlauf M; Vielhaber K; Kahl KG; Broocks A; Voderholzer U; Hohagen F
    J Clin Psychopharmacol; 2008 Oct; 28(5):550-4. PubMed ID: 18794652
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A randomized controlled clinical trial of citalopram versus fluoxetine in children and adolescents with obsessive-compulsive disorder (OCD).
    Alaghband-Rad J; Hakimshooshtary M
    Eur Child Adolesc Psychiatry; 2009 Mar; 18(3):131-5. PubMed ID: 19190958
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Defining cognitive-behavior therapy response and remission in pediatric OCD: a signal detection analysis of the Children's Yale-Brown Obsessive Compulsive Scale.
    Skarphedinsson G; De Nadai AS; Storch EA; Lewin AB; Ivarsson T
    Eur Child Adolesc Psychiatry; 2017 Jan; 26(1):47-55. PubMed ID: 27209422
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sertraline Effects on Striatal Resting-State Functional Connectivity in Youth With Obsessive-Compulsive Disorder: A Pilot Study.
    Bernstein GA; Cullen KR; Harris EC; Conelea CA; Zagoloff AD; Carstedt PA; Lee SS; Mueller BA
    J Am Acad Child Adolesc Psychiatry; 2019 May; 58(5):486-495. PubMed ID: 30768407
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Group cognitive-behavioral therapy versus sertraline for the treatment of children and adolescents with obsessive-compulsive disorder.
    Asbahr FR; Castillo AR; Ito LM; Latorre MR; Moreira MN; Lotufo-Neto F
    J Am Acad Child Adolesc Psychiatry; 2005 Nov; 44(11):1128-36. PubMed ID: 16239861
    [TBL] [Abstract][Full Text] [Related]  

  • 40. N-Acetylcysteine for Pediatric Obsessive-Compulsive Disorder: A Small Pilot Study.
    Li F; Welling MC; Johnson JA; Coughlin C; Mulqueen J; Jakubovski E; Coury S; Landeros-Weisenberger A; Bloch MH
    J Child Adolesc Psychopharmacol; 2020 Feb; 30(1):32-37. PubMed ID: 31800306
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.